SynthesisBrain tumor pathology2021
Prognostic significance of brain invasion in meningiomas: systematic review and meta-analysis.
Synthesis in Brain tumor pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Histopathological predictors of progression-free survival in atypical meningioma: a single-center retrospective cohort and meta-analysis.Brain tumor pathology · 2022Pooled it
- Meningiomas classified as grade 2 due to brain invasion alone have better progression-free survival than other atypical meningiomas.Journal of neuro-oncology · 2026Article
- The relationship between molecular subtypes and magnetic resonance perfusion in patients with brain meningioma.Surgical neurology international · 2025Article
- Multiparameter MRI-based radiomics nomogram for preoperative prediction of brain invasion in atypical meningioma:a multicentre study.BMC medical imaging · 2024Article
- Meningioma recurrence: Time for an online prediction tool?Surgical neurology international · 2024Review
- Radiotherapy and radiosurgery for meningiomas.Neuro-oncology advances · 2023Article
- Meningiomas with CNS invasion.Frontiers in neuroscience · 2023Review
- Brain Invasion and Trends in Molecular Research on Meningioma.Brain tumor research and treatment · 2023Review
- Preoperative surgical risk assessment of meningiomas: a narrative review based on MRI radiomics.Neurosurgical review · 2022Review
- Updated Systematic Review on the Role of Brain Invasion in Intracranial Meningiomas: What, When, Why?Cancers · 2022Review
- The Simpson Grading: Is It Still Valid?Cancers · 2022Review
- Outcomes of Preserving the Hypertrophic Arachnoid Membrane in the Brain-meningioma Interface: Long-term Follow-up.Neurologia medico-chirurgica · 2022Article
- The efficacy of preoperative MRI features in the diagnosis of meningioma WHO grade and brain invasion.Frontiers in oncology · 2022Article
- M2-Macrophage-Derived Exosomes Promote Meningioma Progression through TGF-Journal of immunology research · 2022Article
- Increased proliferation is associated with CNS invasion in meningiomas.Journal of neuro-oncology · 2021Article
- Combining FORGE Score and Histopathological Diagnostic Criteria of Atypical Meningioma Enables Risk Stratification of Tumor Progression.Diagnostics (Basel, Switzerland) · 2021Article
- Review
- Base MRI Imaging Characteristics of Meningioma Patients to Discuss the WHO Classification of Brain Invasion Otherwise Benign Meningiomas.Technology in cancer research & treatmentArticle
- Concordance of fluorescence in situ hybridization, whole-exome sequencing, and chromosomal microarray for evaluating high-risk molecular features in meningiomas.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The WHO 2016 classification introduced brain invasion as a standalone criterion for grade II meningioma (GIIM). We systematically reviewed studies published after 2000 and performed a PRISMA-compliant meta-analysis of the hazard ratios (HRs) for progression-free survival (PFS) between brain-invasive and noninvasive meningiomas. In five studies that included both benign and higher-grade meningiomas, brain invasion was a significant risk factor for recurrence (HR = 2.45, p = 0.0004). However, in 3 studies comparing "brain-invasive meningioma with otherwise benign histology (BIOB)" with grade I meningioma, brain invasion was not a significant predictor of PFS (HR = 1.49, p = 0.23). Among GIIM per the WHO 2000 criteria, brain invasion was a significant predictor of shorter PFS than noninvasive GIIM (HR = 3.40, p = 0.001) but not per the WHO 2016 criteria (HR 1.13, p = 0.54), as the latter includes BIOB. Meta-regression analysis of seven studies of grade II meningioma showed that more frequent BIOB was associated with lower HRs (p < 0.0001). Hence, there is no rationale for brain invasion as a standalone criterion for grade II meningioma, although almost all studies were retrospective and exhibited highly heterogeneous HRs due to differences in brain-tumor interface data availability.
Indexed as
Identifiers
33403457What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.